384 results
DEFA14A
IMGN
Immunogen, Inc.
29 Jan 24
Additional proxy soliciting materials
5:01pm
opportunities or strategic transactions; risks associated with litigation relating to the Merger; risk that shareholder litigation may result in significant
8-K
IMGN
Immunogen, Inc.
29 Jan 24
Other Events
5:00pm
ImmunoGen’s ability to pursue certain business opportunities or strategic transactions; risks associated with litigation relating to the Merger; risk … that shareholder litigation may result in significant costs of defense, indemnification and liability; the possibility that competing offers may be made
DEFA14A
IMGN
Immunogen, Inc.
24 Jan 24
Additional proxy soliciting materials
4:57pm
, or the Proxy Statement (such letters, the “Demands” and, collectively with the Merger Actions, the “Litigation Matters”).
ImmunoGen believes … that the claims asserted in the Litigation Matters are without merit and that no further disclosure beyond that already contained in the Proxy Statement
8-K
IMGN
Immunogen, Inc.
24 Jan 24
Other Events
4:55pm
, the “Litigation Matters”).
ImmunoGen believes that the claims asserted in the Litigation Matters are without merit and that no further disclosure beyond … that already contained in the Proxy Statement is required under applicable law to supplement the Proxy Statement, as claimed in the Litigation Matters
DEFA14A
IMGN
Immunogen, Inc.
8 Jan 24
Additional proxy soliciting materials
4:12pm
transactions; risks associated with litigation relating to the Merger; risk that shareholder litigation may result in significant costs of defense
8-K
b783536kcya
8 Jan 24
Other Events
4:11pm
DEFM14A
qyjvjcrgd7y5ib51mhzw
2 Jan 24
Proxy related to merger
4:26pm
PREM14A
5b7cevl5 qs
21 Dec 23
Preliminary proxy related to merger
4:52pm
DEFA14A
nmg8fxxgqr7sfcthfn
21 Dec 23
Additional proxy soliciting materials
3:54pm
DEFA14A
y03d1ow6d3za0s5g1 a5
30 Nov 23
Additional proxy soliciting materials
4:08pm
DEFA14A
EX-2.1
4p9hgnvpo1v
30 Nov 23
Additional proxy soliciting materials
4:07pm
DEFA14A
ehk5rxpvlbdwu
30 Nov 23
Additional proxy soliciting materials
4:07pm
DEFA14A
EX-99.1
x25w6ee
30 Nov 23
Additional proxy soliciting materials
4:07pm
8-K
EX-2.1
3c4wip27d 7eez
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
8-K
EX-99.1
zje1f8l7vsuy 15tu
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
8-K
f0r5ljsgt86jc7wg7t
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
8-K
EX-1.1
db027r sd
5 May 23
Entry into a Material Definitive Agreement
5:15pm
424B5
q0kwto
5 May 23
Prospectus supplement for primary offering
4:49pm